Physician profile
Scott E Mattson
NPI 1477523645
$1,668.70
in general payments reported to CMS, 2019-2025
21 companies · $160 in 2025
The $160 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $913 · 2021: $12.87 · 2022: $380 · 2023: $183 · 2024: $20.22 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $343 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $343.01 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $223.61 | 2022 | |
| Abbott Laboratories | $214.26 | 2022-2023 | Cardiomems |
| Pfizer INC. | $197.25 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.93 | 2019 | |
| Ge Healthcare | $120.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $110.33 | 2019-2023 | Leqvio |
| Akcea Therapeutics, INC. | $101.90 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $91.33 | 2019 | |
| United Therapeutics Corporation | $89.41 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.31 | 2019-2025 | |
| Lantheus Medical Imaging, INC. | $47.78 | 2022 | |
| Eli Lilly and Company | $47.33 | 2019 | |
| Gilead Sciences, INC. | $38.24 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $27.80 | 2019 | |
| Canon Medical Systems USA, INC. | $27.38 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $26.11 | 2019 | |
| Edwards Lifesciences Corporation | $23.85 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abbvie INC. | $19.46 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $15.55 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.87 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Mattson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.